Chapple Alison, Ziebland Sue, Hewitson Paul, McPherson Ann
Department of Primary Health Care, Old Road Campus, University of Oxford, Old Road, Headington, Oxford, England, UK.
Qual Health Res. 2008 Jan;18(1):56-64. doi: 10.1177/1049732307309000.
The prostate specific antigen (PSA) test is widely used to screen men for prostate cancer, but its value in diagnosing prostate cancer in asymptomatic men is controversial. In 2001, the U.K. Department of Health introduced the Prostate Cancer Risk Management Programme (PCRMP), through which men are given relatively detailed information before they make a final decision about a test. Little is known about men's experiences of the test since this program was introduced. We report an analysis of interviews with 30 men who were tested, or considered having a test, since the PCRMP was introduced. Our analysis suggests that men's views of the PSA test are dominated by their construction of testing as responsible health behavior and their perception of PSA as "just a blood test." Men's accounts also suggest that poor communication about the uncertainty of the test--and about treatment for prostate cancer--also persists.
前列腺特异性抗原(PSA)检测被广泛用于男性前列腺癌的筛查,但其在无症状男性前列腺癌诊断中的价值存在争议。2001年,英国卫生部推出了前列腺癌风险管理计划(PCRMP),通过该计划,男性在最终决定是否进行检测之前会获得相对详细的信息。自该计划推出以来,对于男性接受检测的体验了解甚少。我们报告了对30名自PCRMP推出以来接受检测或考虑进行检测的男性的访谈分析。我们的分析表明,男性对PSA检测的看法主要受他们将检测视为负责任的健康行为的观念以及他们将PSA视为“仅仅是一项血液检测”的认知所主导。男性的叙述还表明,关于检测不确定性以及前列腺癌治疗方面的沟通不畅问题仍然存在。